NASDAQ:INDV Indivior (INDV) Stock Price, News & Analysis $12.20 -0.15 (-1.21%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$12.18▼$12.3050-Day Range$10.19▼$16.7952-Week Range$9.14▼$23.89Volume31,126 shsAverage Volume260,832 shsMarket Capitalization$1.68 billionP/E Ratio1,220.00Dividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Indivior alerts: Email Address Indivior MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.2% Upside$23.00 Price TargetShort InterestHealthy0.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 20 Articles This WeekInsider TradingN/AProj. Earnings Growth20.44%From $1.81 to $2.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 starsMedical Sector228th out of 924 stocksDrug Manufacturers - Specialty & Generic Industry1st out of 1 stocks 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has only been the subject of 2 research reports in the past 90 days.Read more about Indivior's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.36% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indivior has recently decreased by 19.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 2.8 News and Social Media Coverage News SentimentIndivior has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Indivior this week, compared to 3 articles on an average week.Search Interest2 people have searched for INDV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Indivior to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have not sold or bought any company stock.Percentage Held by Institutions60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Indivior are expected to grow by 20.44% in the coming year, from $1.81 to $2.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 1,235.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 1,235.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 139.87.Read more about Indivior's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.You need to check out the full story right here. About Indivior Stock (NASDAQ:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesAugust 22 at 5:45 AM | prnewswire.comInvestors in Indivior PLC Should Contact The Gross Law Firm Before October 1, 2024 to Discuss Your Rights - INDVAugust 21 at 7:30 PM | prnewswire.comRosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their RightsAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 21 at 1:28 PM | globenewswire.comThe Gross Law Firm Notifies Indivior PLC Investors of a Class Action Lawsuit and Upcoming Deadline – INDVAugust 21 at 11:20 AM | globenewswire.comINDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law FirmAugust 21 at 11:00 AM | prnewswire.comINDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud LawsuitAugust 20 at 5:45 AM | prnewswire.comIndivior PLC Class Action: Levi & Korsinsky Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024 - INDVAugust 19 at 4:00 PM | globenewswire.comINDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 19 at 12:57 PM | globenewswire.comLevi & Korsinsky Reminds Indivior PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024 – INDVAugust 19 at 12:00 PM | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)August 19 at 5:45 AM | prnewswire.comThe Gross Law Firm Notifies Indivior PLC Investors of a Class Action Lawsuit and Upcoming Deadline - INDVAugust 18, 2024 | globenewswire.comShareholder Rights Law Firm Robbins LLP Urges INDV Stockholders to Contact the Firm for Information About the Indivior PLC Class ActionAugust 18, 2024 | prnewswire.comINDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 18, 2024 | globenewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Indivior PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action – INDVAugust 17, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines - INDVAugust 16, 2024 | stockhouse.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Indivior PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action - INDVAugust 16, 2024 | prnewswire.comINDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud LawsuitSee More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/25/2024Today8/22/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolNASDAQ:INDV CUSIPN/A CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees1,000Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$24.00 Low Stock Price Target$22.00 Potential Upside/Downside+86.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio1,235.00 Forward P/E Ratio6.82 P/E GrowthN/ANet Income$2 million Net Margins-12.29% Pretax Margin-16.65% Return on Equity-654.82% Return on Assets13.01% Debt Debt-to-Equity Ratio23.50 Current Ratio0.85 Quick Ratio0.68 Sales & Book Value Annual Sales$1.15 billion Price / Sales1.48 Cash Flow$1.65 per share Price / Cash Flow7.48 Book Value($0.88) per share Price / Book-14.03Miscellaneous Outstanding Shares137,879,000Free FloatN/AMarket Cap$1.70 billion OptionableNot Optionable Beta0.69 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsAlvotechNASDAQ:ALVOWBiofronteraNASDAQ:BFRIWClever LeavesNASDAQ:CLVRWCyclo TherapeuticsNASDAQ:CYTHWProcaps GroupNASDAQ:PROCWView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 162,800 shares on 8/16/2024Ownership: 0.000%Mackenzie Financial CorpSold 57,185 shares on 8/15/2024Ownership: 0.361%Millennium Management LLCBought 160,282 shares on 8/15/2024Ownership: 0.358%AXA S.A.Sold 37,254 shares on 8/15/2024Ownership: 0.175%The Manufacturers Life Insurance Company Sold 1,223 shares on 8/15/2024Ownership: 0.010%View All Institutional Transactions INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at $15.27 at the start of the year. Since then, INDV stock has decreased by 19.1% and is now trading at $12.35. View the best growth stocks for 2024 here. How were Indivior's earnings last quarter? Indivior PLC (NASDAQ:INDV) posted its earnings results on Thursday, July, 25th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.04. The business had revenue of $299 million for the quarter, compared to analysts' expectations of $285.90 million. Indivior had a negative trailing twelve-month return on equity of 654.82% and a negative net margin of 12.29%. Who are Indivior's major shareholders? Top institutional shareholders of Indivior include Liontrust Investment Partners LLP (0.99%), Toronto Dominion Bank (0.83%), Mackenzie Financial Corp (0.36%) and Millennium Management LLC (0.36%). How do I buy shares of Indivior? Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INDV) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDV Stock Alerts